Clearly, the interface between managed care and the Pharmaceutical and Medicine Manufacturing (PMM) industries, is important for the health of either industry. In common tare he issues of appropriateness, compliance, cost-effectiveness, patient selection and symbiosis among all relevant players on the health care stage (ACCESS). I say, put the practicing clinician on the PMM team and visa versa—How and Why?
- This article is posted in:
The issues of appropriateness, compliance, cost-effectiveness, patient selection and symbiosis (ACCESS) are vital to both health care and pharmaceutical industries and define their possible relationship. "At this moment, Medicare’s rules – yes, the same Medicare that’s slated to go broke in a decade or so – forbid it to consider cost in its coverage decisions.
Raymond V. Gilmartin, the former Chairman, President and Chief Executive Officer of Merck & Co., Inc. (1994-2005) in a speech January 19, 2000 gave commentary about the Pharmaceutical and Medicine Manufacturing (PMM) industry. While the original reference ar Merck.com has been pulled, the following is faithful to his statements. Mr. Gilmartin defends U.S.
Are expensive pharmaceuticals any better than first-generation antipsychotics? "On September 18, 2007, a few dozen neuroscientists, psychiatrists, and drug-company executives gathered in a hotel conference room in Brussels to hear some startling news. It had to do with a class of drugs known as atypical or second-generation antipsychotics, which came on the market in the early nineties.
The Pharmaceutical and Medicine Manufacturing (PMM) industry--an opportunity for synergism with health care. "At the same time that unprecedented progress in pharmaceutical research and development is producing new and better medicines for the treatment and prevention of disease – people are asking tough and legitimate questions about the role and responsibility of the pharmaceutical industry in expanding access to the results of this research."